3:11 PM
 | 
Mar 07, 2018
 |  BC Extra  |  Preclinical News

Selectively inhibiting GSK3's double genes for AML

Researchers at the Broad Institute of MIT and Harvard and colleagues found a way to design highly selective glycogen synthase kinase 3 inhibitors that target one of two forms of the gene. The approach could help treat acute myelogenous leukemia while circumventing toxicities associated with dual inhibition of GSK3 paralogs.

GSK3 is encoded across GSK3 alpha (GSK3A) located on chromosome 19 and GSK3 beta (GSK3B) located...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >